A Phase 1 interventional study of SCH 727965 in Solid Tumors, Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Merck Sharp & Dohme LLC · Phase 1, Interventional, and Treatment
The study will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered as an intravenous infusion on Days 1, 8 and 15 of each 28 day cycle in participants with solid tumors, non Hodgkins lymphoma, multiple myeloma or chronic lymphocytic leukemia.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 123 is above the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,111 studies on the registry; 130 are open to participants now.
Of its 488 completed or terminated interventional studies of FDA-regulated products, 361 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
For advanced solid tumors, non-Hodgkin's lymphoma, or multiple myeloma:
Subjects with multiple myeloma must have measurable disease defined as:
Participants with lower M protein values or nonsecretory myeloma are eligible if measurable disease can be established within 4 weeks prior to start of treatment, such as:
For B-cell chronic lymphocytic leukemia (B-CLL):
Exclusion Criteria:
Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
Drug: SCH 727965
Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
Drug: SCH 727965
Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
Drug: SCH 727965
Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity.
Time frame: End of trial
In participants with advanced solid tumors, non Hodgkin's lymphoma or multiple myeloma, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.
Time frame: End of trial
No study locations are listed for this record.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC